This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A merger involving two US digital health specialists and a blank cheque company has created a telemedicine player, called UpHealth, that is valued at more than $1.3 billion. The three-way deal combines UpHealth – which provides patient care management, telemedicine and digital pharmacy services and gives its name to the new group – with CloudBreak, which provides a video consultation platform for doctors and patients.
The new EU Pharmaceutical Strategy, adopted today by the European Commission, is designed to improve and accelerate patientsâ access to safe and affordable medicines and address unmet medical needs in the areas of antimicrobial resistance, cancer, and rare diseases.
Citalopram is a popular antidepressant prescribed in the UK. It is also one of the most prescribed medicines in the UK. Although escitalopram is ‘related’ to citalopram, it significantly less prescribed. Today I will review differences between escitalopram and citalopram. Escitalopram vs citalopram, a summary of the post: Escitalopram vs citalopram: legal status.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
A new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children as young as six if they have specific gene mutations. The regulator has given a green light to use of Symkevi (tezacaftor/ivacaftor) with Vertex’ Kalydeco (ivacaftor) in patients ages six years and older who have two copies of the F508del mutation in the CFTR gene, or one F508del copy and one of 14 other so-called “minimal function” mutations in CFTR.
The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidateâs potential in overcoming resistance of a cancer drug.
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NS
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NS
Amanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of the patient voice is stoking change in the rare disease space. New models of drug development are fuelling life-changing advantages in the rare disease space, previously an economic no-go area for pharma and biotech companies. That was among the discussion points during Fighting Rare Diseases – The Science, Economics and the Patients , a webinar hosted by o2h Group.
The Hague — To help pharmacists advise people on COVID-19 tests, the International Pharmaceutical Federation (FIP), has today issued a guidance document. The guidance has been produced by FIP’s SARS-CoV-2 Testing Working Group, which has evaluated the diagnostic testing methods and devices currently available. The document covers how different types of diagnostic test work and the interpretation of results.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said. Following a briefing with management, a team of analysts led by Peter Welford said that the big Swiss pharma will be propped up by its psoriasis and infectious diseases blockbuster Cosentyx for some time.
The agency has given the go-ahead for use of baricitinib in conjunction with remdesivir for treating patients hospitalized with severe cases of the virus.
Medisafe, a leading digital therapeutics company specializing in digital companions, has been selected by UCB to develop branded digital drug companions for its antiepileptic medications, with greater capabilities to expand across additional brands. The digital companions streamline support for patients to access financial assistance, patient diaries, and doctor discussion guides throughout their treatment journey.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma sales is set to change forever. To keep afloat in the current climate, teams need to embrace flexibility and remember that traditional content won’t work in new contexts, say experts from Syneos Health. Selling in a socially-distanced world is about more than simply taking conversations online – it requires a wholesale change in how sales teams operate and the kinds of content they use.
Intelligent Tissue Group has launched its Intelligent Clinical trials facility to help assess the effectiveness and safety of potential new treatments.
I was incredibly excited to pass the 1,000,000 podcast download milestone recently! I had no idea that there would be that many people that would be interested in learning about drugs. I have been blessed to receive many thank you’s and messages of appreciation for the podcast and the blog. These messages have been mini-rocket […]. The post An Unexpected Milestone – Thanksgiving Thank You appeared first on Med Ed 101.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
COVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning how to overcome the challenges of 2020 will serve the industry well for years to come. As part of our EU Leader series, Christian Pawlu, head of strategy, portfolio and BD&L at Sandoz, told us about how securing supply in a time of crisis will ensure future access, build resilience, and transform relationships.
The clinical site services provider continues its series of strategic company purchases by bringing the Irish trial technologies firm under its umbrella.
Working with geriatric patients and providers in primary care, I definitely have to stay up to date with regards to diabetes therapy. There have been a couple of diabetes updates in 2020 that I wanted to make sure you were aware of. The SGLT2 inhibitors is a class of medication that is undergoing a lot […]. The post Two Diabetes Updates in 2020 appeared first on Med Ed 101.
The developer of Russia’s COVID-19 vaccine Sputnik V has pledged to make it available for less than $10 per dose – or $20 per two-dose course – on the same day as revealing new clinical data with the shot. Sputnik V ’s efficacy has remained high at 91.4% according to the latest analysis, which comes from almost 19,000 subjects who were assessed seven days after the second dose of the vaccine, administered 28 days after the first.
This year, clascoterone (brand name: Winlevi) has been approved by The United States Food and Drug Administration (FDA) for treatment of acne in the US. In the UK, there are several options for the management of acne, including topical preparations and oral antibiotics. In this post, I will review clascoterone and compare it to other treatments available in the UK.
The UK’s pharma industry trade body has warned that Brexit could derail the government’s efforts to get coronavirus vaccines to the population, but welcomed other measures in this week’s spending review aimed at reviving the economy after the pandemic. In the build-up to chancellor Rishi Sunak’s announcement in the House of Commons, the Association of the British Pharmaceutical Industry (ABPI) chief executive Richard Torbett warned that a no-deal Brexit could disrupt supplies of vaccines.
The company has received a $500,000 grant from the COVID-19 Therapeutics Accelerator to develop manufacturing processes for the antiviral drug remdesivir.
Pharmaceutical marketing budgets are going through a period of readjustment as companies explore and exploit a myriad of different digital channels to deliver content to, and engage with, their doctors and other audiences. The average allocation to digital channels with marketing budgets has doubled since 2016, up to 34% for 2020 according to Indegene research, and over a third of companies expect digital budget allocations to increase by more than 50% over the next three years.
The FDA has approved a new use for Xofluza (baloxavir marboxil) from Roche’s Genentech unit, to prevent people developing flu after coming into contact with an infectious person. Xofluza has already been on the market for two years, and already had licensed uses to treat uncomplicated flu and those at high risk of complications. With this third indication, Xofluza has become the first single-dose medicine approved for this new use also known as post-exposure prophylaxis.
Y-mAbs Therapeutics has claimed its first product approval, getting a green light from the FDA for Danyelza for the rare cancer neuroblastoma. Danyelza (naxitamab) is an antibody that targets GD2, a protein found on the surface of some tumour cells, and it has been cleared by the US regulator for use alongside GM-CSF – a cytokine drug – as a second-line neuroblastoma treatment after a priority review.
AstraZeneca may have tried a positive spin on the trial mistake that led to the accidental discovery of the low dose COVID-19 vaccine regime with the highest efficacy– but the revelation has drawn a mixed response from commentators. The company’s share price has tumbled since the announcement of the trial results from AZD-1222 at the beginning of the week, reflecting an overall loss of confidence in the company’s handling of the trial.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
138 
Let's personalize your content